253 related articles for article (PubMed ID: 33777778)
21. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.
Park HY; Lee SB; Yoo HY; Kim SJ; Kim WS; Kim JI; Ko YH
Oncotarget; 2016 Dec; 7(52):86433-86445. PubMed ID: 27835906
[TBL] [Abstract][Full Text] [Related]
22.
Zhou J; Zuo M; Li L; Li F; Ke P; Zhou Y; Xu Y; Gao X; Guan Y; Xia X; Yi X; Zhang X; Huang Y
Front Oncol; 2022; 12():824632. PubMed ID: 35223507
[TBL] [Abstract][Full Text] [Related]
23. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farré B; Balagué O; Celis V; Nadeu F; Salmerón-Villalobos J; Andrés M; Martin-Guerrero I; Garrido-Pontnou M; Gaafar A; Suñol M; Bárcena C; Garcia-Bragado F; Andión M; Azorín D; Astigarraga I; Sagaseta de Ilurdoz M; Sábado C; Gallego S; Verdú-Amorós J; Fernandez-Delgado R; Perez V; Tapia G; Mozos A; Torrent M; Solano-Páez P; Rivas-Delgado A; Dlouhy I; Clot G; Enjuanes A; López-Guillermo A; Galera P; Oberley MJ; Maguire A; Ramsower C; Rimsza LM; Quintanilla-Martinez L; Jaffe ES; Campo E; Salaverria I
Blood; 2020 Jan; 135(4):274-286. PubMed ID: 31738823
[TBL] [Abstract][Full Text] [Related]
24. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
[TBL] [Abstract][Full Text] [Related]
25. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.
Juskevicius D; Lorber T; Gsponer J; Perrina V; Ruiz C; Stenner-Liewen F; Dirnhofer S; Tzankov A
Leukemia; 2016 Dec; 30(12):2385-2395. PubMed ID: 27198204
[TBL] [Abstract][Full Text] [Related]
26. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive characterization of driver genes in diffuse large B cell lymphoma.
Fan Z; Pei R; Sha K; Chen L; Wang T; Lu Y
Oncol Lett; 2020 Jul; 20(1):382-390. PubMed ID: 32565964
[TBL] [Abstract][Full Text] [Related]
28. A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
Bosch M; Akhter A; Chen BE; Mansoor A; Lebrun D; Good D; Crump M; Shepherd L; Scott DW; Stewart DA
Haematologica; 2018 Feb; 103(2):288-296. PubMed ID: 29097500
[TBL] [Abstract][Full Text] [Related]
29. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.
Broséus J; Chen G; Hergalant S; Ramstein G; Mounier N; Guéant JL; Feugier P; Gisselbrecht C; Thieblemont C; Houlgatte R
Oncotarget; 2016 Dec; 7(51):83987-84002. PubMed ID: 27276707
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
Gebauer N; Bernard V; Gebauer W; Thorns C; Feller AC; Merz H
Leuk Lymphoma; 2015 Jan; 56(1):179-85. PubMed ID: 24679006
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of primary
Greenawalt DM; Liang WS; Saif S; Johnson J; Todorov P; Dulak A; Enriquez D; Halperin R; Ahmed A; Saveliev V; Carpten J; Craig D; Barrett JC; Dougherty B; Zinda M; Fawell S; Dry JR; Byth K
Oncotarget; 2017 Nov; 8(59):99237-99244. PubMed ID: 29245897
[TBL] [Abstract][Full Text] [Related]
32. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
33. Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.
Nijland M; Seitz A; Terpstra M; van Imhoff GW; Kluin PM; van Meerten T; Atayar Ç; van Kempen LC; Diepstra A; Kok K; van den Berg A
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463380
[TBL] [Abstract][Full Text] [Related]
34. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M; Calzada O; Xavier AC; Zhou Z; Hossain NM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Barta SK; Chhabra S; Lansigan F; Mehta A; Jaglal MV; Evens AM; Flowers CR; Cohen JB; Fenske TS; Hamadani M; Costa LJ
Cancer; 2017 Nov; 123(22):4411-4418. PubMed ID: 28749548
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
36. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
[TBL] [Abstract][Full Text] [Related]
37. Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?
Boiza-Sánchez M; Manso R; Balagué O; Chamizo C; Askari E; Salgado RN; Blas-López C; Aguirregoicoa-García E; Menárguez J; Santonja C; Adrados M; Limeres-González MÁ; Piris MÁ; Rodríguez-Pinilla SM
PLoS One; 2020; 15(11):e0241634. PubMed ID: 33180881
[TBL] [Abstract][Full Text] [Related]
38. CD58 alterations govern antitumor immune responses by inducing PD-L1 and IDO in diffuse large B-cell lymphoma.
Xu X; Zhang Y; Lu Y; Zhang X; Zhao C; Wang J; Guan Q; Feng Y; Gao M; Yu J; Song Z; Liu X; Golchehre Z; Li L; Ren W; Pan-Hammarström Q; Zhang H; Wang X
Cancer Res; 2024 Apr; ():. PubMed ID: 38635903
[TBL] [Abstract][Full Text] [Related]
39. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
40. Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.
Suehara Y; Sakata-Yanagimoto M; Hattori K; Kusakabe M; Nanmoku T; Sato T; Noguchi M; Chiba S
Cancer Sci; 2019 Oct; 110(10):3375-3381. PubMed ID: 31436356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
